Asia-Pacific Oral Anti-Diabetic Drug Market Size and Share
Market Overview
| Study Period | 2021 - 2032 |
|---|---|
| Forecast Data Period | 2027 - 2032 |
| Historical Data Period | 2021 - 2025 |
| Base Year Market Size (2026) | USD 26.97 Billion |
| Market Size (2027) | USD 27.81 Billion |
| Market Size (2032) | USD 32.39 Billion |
| Growth Rate (2027 - 2032) | 3.10 % |
Major Players *Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. | |
Asia-Pacific Oral Anti-Diabetic Drug Market Analysis by Mordor Intelligence
The Asia-Pacific Oral Anti-Diabetic Drug Market size is projected to be USD 26.97 billion in 2026, USD 27.81 billion in 2027, and reach USD 32.39 billion by 2032, growing at a CAGR of 3.10% from 2027 to 2032.
The Asia-Pacific market for oral anti-diabetic drugs is poised for substantial growth, driven by an aging demographic and escalating diabetes rates. Factors such as heightened stress, sedentary lifestyles, smoking, and excessive alcohol consumption are primary contributors to the rising prevalence of diabetes, leading to elevated blood sugar levels.
The region's escalating diabetes rates are a key driver for the growing demand for oral anti-diabetic medications. For instance, projections from IDF indicate that the number of individuals with diabetes in Southeast Asia is set to surge by 68%, reaching around 152 million by 2045. Additionally, the diabetes prevalence rate is expected to surge by 30%, reaching 11.3% in 2045. Moreover, health-related expenditures for diabetes are expected to rise from USD 17,675.4 million in 2030 to USD 21,200.0 million in 2045. This surge in health-related spending, coupled with the climbing diabetes prevalence, is set to underpin the market's expansion.
Advancements in drug delivery technologies, particularly in oral formats, are poised to propel market growth further. For instance, in May 2024, an international team led by Australian researchers introduced a nanotechnology-based system. This innovation paves the way for a future where individuals with diabetes could potentially consume oral insulin. The researchers highlight that this new form of insulin could be ingested via a tablet or even concealed within a piece of chocolate, offering a more palatable option, especially for elderly diabetic patients averse to injections.
The Asia-Pacific oral anti-diabetic drug market is progressing significantly. The rising prevalence of diabetes and advancements in drug delivery technologies will continue to drive demand and innovation. The market is expected to benefit from rising health-related expenditures and the development of more accessible and user-friendly medication formats.
Note: Market numbers in this report are based on Mordor Intelligence's proprietary estimation framework, which combines nine months of actuals with Q4 projections for base year 2026.
Asia operates as part of an interconnected international environment rather than as a self-contained unit. The oral anti-diabetic drugs market research by Mordor Intelligence places together all major regional developments across the globe within that wider frame.
Asia-Pacific Oral Anti-Diabetic Drug Market Trends and Insights
Biguanide Segment is Estimated To witness Significant Growth Over the Forecast Period
The biguanide segment was expected to witness significant growth in 2023 owing to increased regulatory approvals and financial ease for increasing the accessibility of affordable drugs.
Metformin, a biguanide, is primarily used to manage type 2 diabetes. It is also prescribed off-label for conditions like insulin resistance. Since its introduction, metformin has successfully treated a significant number of patients. Endorsed as a first-line prescription by IDF, it boasts a commendable risk/benefit profile.
Given its track record, metformin is the most prescribed oral anti-diabetic globally, accounting for 45-50% of all prescriptions and benefiting over 150 million individuals annually. Its dominance is attributed to a combination of factors, including a well-established safety profile, robust clinical efficacy, high patient adherence, affordability, and widespread availability.
Regulatory endorsements play a pivotal role in bolstering market growth. For instance, in June 2023, the US FDA greenlit Jardiance (empagliflozin) and Synjardy (empagliflozin with metformin) for children aged 10 and above with type 2 diabetes, marking a significant stride in pediatric diabetes treatment.
The biguanide segment, led by metformin, dominates the North American oral anti-diabetic drugs market. The combination of clinical efficacy, affordability, and strong regulatory support ensures its sustained prominence and growth in the market.
China is Expected to Hold a Significant Market Share
China's oral anti-diabetic drug market is surging, driven by a rising diabetic population. With its population size, the nation has become an attractive opportunity for global pharmaceutical players for their product launches. For instance, in June 2023, China's NMPA approved AstraZeneca's Xigduo XR, a once-daily fixed-dose combination containing dapagliflozin and metformin hydrochloride. This approval was specifically for treating adults with type-2 diabetes (T2D) as an adjunct to diet and exercise aimed at enhancing glycaemic control.
Moreover, increasing focus on diabetic drug development in the Chinese market is set to propel market growth. For instance, in May 2024, Innovent Biologics Inc. announced encouraging outcomes from the Phase 3 clinical trial (DREAMS-2) evaluating mazdutide. This drug is a dual agonist targeting the glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR); it showcased efficacy in Chinese subjects with type 2 diabetes (T2D).
The combination of a growing diabetic population and increased drug development activities positions China as a significant player in the Asia-Pacific oral anti-diabetic drug market. The country's strategic importance is expected to continue attracting major pharmaceutical companies, further driving market growth.
Competitive Landscape
The Asia-Pacific oral anti-diabetes drug market is consolidated, with a few major manufacturers like Eli Lilly and Company, AstraZeneca, Sanofi, and Janssen Pharmaceuticals having a global market presence. In contrast, the remaining manufacturers are confined to the other local or regional markets. Companies are focusing on innovations in diabetes drugs.
Asia-Pacific Oral Anti-Diabetic Drug Industry Leaders
-
Sanofi
-
Novo Nordisk A/S
-
Takeda Pharmaceutical Company Limited
-
Astellas Pharma Inc.
-
AstraZeneca
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- May 2024: Chinese regulators approved Eli Lilly and Company's diabetes drug, Tirzepatide, setting the stage for a competition with Novo Nordisk. Novo Nordisk had secured approval for its flagship diabetes drug, Ozempic, in the vast Asian market in 2021.
- October 2023: Glenmark Pharmaceuticals unveiled a novel triple-fixed-dose combination (FDC) drug for diabetes treatment. Its offering, Zita, combines Teneligliptin, Dapagliflozin, and Metformin.
Asia-Pacific Oral Anti-Diabetic Drug Market Report Scope
The Asia-Pacific oral anti-diabetic drug market is segmented into drugs and geography. By drugs, the market is segmented into biguanides, alpha-glucosidase inhibitors, dopamine-d2 receptor agonists, sodium-glucose cotransport-2 (SGLT-2) inhibitor, dipeptidyl peptidase-4 (DPP-4) inhibitors, sulfonylureas, and meglitinides. By geography, the market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia-Pacific. The report offers the value (USD) for all the above segments.
| Biguanides | |
| Alpha-Glucosidase Inhibitors | |
| Dopamine D2 Receptor Agonist | |
| SGLT-2 Inhibitors | Invokana (Canagliflozin) |
| Jardiance (Empagliflozin) | |
| Farxiga/Forxiga (Dapagliflozin) | |
| Others | |
| DPP-4 inhibitors | Onglyza (Saxagliptin) |
| Tradjenta (Linagliptin) | |
| Vipidia/Nesina(Alogliptin) | |
| Galvus (Vildagliptin) | |
| Sulfonylureas | |
| Meglitinides |
| Adult |
| Geriatic |
| Pediatric |
| China |
| Japan |
| India |
| Australia |
| South Korea |
| Rest of Asia-Pacific |
| By Drugs Type | Biguanides | |
| Alpha-Glucosidase Inhibitors | ||
| Dopamine D2 Receptor Agonist | ||
| SGLT-2 Inhibitors | Invokana (Canagliflozin) | |
| Jardiance (Empagliflozin) | ||
| Farxiga/Forxiga (Dapagliflozin) | ||
| Others | ||
| DPP-4 inhibitors | Onglyza (Saxagliptin) | |
| Tradjenta (Linagliptin) | ||
| Vipidia/Nesina(Alogliptin) | ||
| Galvus (Vildagliptin) | ||
| Sulfonylureas | ||
| Meglitinides | ||
| By Patient Type | Adult | |
| Geriatic | ||
| Pediatric | ||
| Geography | China | |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
Key Questions Answered in the Report
How big is the Asia-Pacific Oral Anti-Diabetic Drug Market?
The Asia-Pacific Oral Anti-Diabetic Drug Market size is expected to reach USD 27.81 billion in 2027 and grow at a CAGR of 3.10% to reach USD 32.39 billion by 2032.
What is the current Asia-Pacific Oral Anti-Diabetic Drug Market size?
In 2026, the Asia-Pacific Oral Anti-Diabetic Drug Market size is expected to reach USD 26.97 billion.
Who are the key players in Asia-Pacific Oral Anti-Diabetic Drug Market?
Sanofi, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc. and AstraZeneca are the major companies operating in the Asia-Pacific Oral Anti-Diabetic Drug Market.
What years does this Asia-Pacific Oral Anti-Diabetic Drug Market cover, and what was the market size in 2025?
In 2025, the Asia-Pacific Oral Anti-Diabetic Drug Market size was estimated at USD 26.16 billion. The report covers the Asia-Pacific Oral Anti-Diabetic Drug Market historical market size for years: 2021, 2022, 2023, 2024, and 2025. The report also forecasts the Asia-Pacific Oral Anti-Diabetic Drug Market size for years: 2027, 2028, 2029, 2030, 2031, and 2032.